Cimerli (ranibizumab-eqrn)

Adult Dosing .

Dosage forms:  INJ (vial): 0.3 mg per 0.05 mL, 0.5 mg per 0.05 mL

Special Note

[formulation clarification]

Info: nonproprietary name = ranibizumab-eqrn

age-related macular degeneration, neovascular

[0.5 mg intravitreal injection qmo]

Info: may decr. to 0.5 mg q2mo after 3 doses or 0.5 mg q3mo after 4 doses; less frequent dosing not as effective as qmo

macular edema, retinal vein occlusion-associated

[0.5 mg intravitreal injection qmo]

diabetic macular edema

[0.3 mg intravitreal injection qmo]

diabetic retinopathy

[0.3 mg intravitreal injection qmo]

myopic choroidal neovascularization

[0.5 mg intravitreal injection qmo for up to 3mo]

Info: may repeat tx based on response

renal dosing

[no adjustment]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

hepatic dosing

[not defined]

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.